Having shifted its commercial and research focus from cancer to non-cancer hemolytic rare diseases last year, Agios Pharmaceuticals, Inc. is now paring back on drug discovery research to focus on advancing a later-stage portfolio of drugs, including potentially ones that will be externally sourced. It's a significant change for a company that was initially established in 2008 as a drug discovery company, but CEO Jackie Fouse said it is all part of an evolution to develop a sustainable business model and tap current market opportunities.
Agios CEO Fouse On Building A Sustainable Business Model
In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.
More from Strategy
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.